HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Inclusion Criteria:

1. ECOG performance status 0 or 1
2. Histological or cytologically confirmed pancreatic cancer that has not been previouslytreated in the metastatic disease.
3. Life expectancy of greater than or equal to3 months.
4. At least one measurable lesion is present according to the efficacy evaluationcriteria for pancreatic cancer (RECIST 1.1)
5. Able and willing to provide a written informed consent

Exclusion Criteria:

1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium,including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas,pancreatoblastoma, and solid-pseudopapillary tumor;
2. Known history of central nervous system (CNS) metastases.
3. Severe infection (> CTCAE grade 2), such as severe pneumonia, bacteremia, infectioncomplications, etc. requiring inpatient treatment, occurred within four weeks beforeenrollment, and symptoms and signs of infection requiring intravenous antibiotictherapy (except for prophylactic antibiotics) occurred within two weeks beforeenrollment;
4. Patients with cardiac clinical symptoms or diseases that are not well controlled, suchas: (1) Patients with NYHA class 2 and above cardiac failure; (2) unstable angina; (3)myocardial infarction that occurred within 6 months; (4) clinically significantsupraventricular or ventricular arrhythmia requiring treatment or intervention.